NDAOTICSOLUTION/DROPSPriority Review
Approved
Sep 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
8
Data completeness
6/8 — Strong
Priority Review
CLOTIC (clotrimazole) by Inpharmus is 12. Approved for candidiasis, oral candidiasis, vulvovaginal candidiasis and 2 more indications. First approved in 2025.
Drug data last refreshed 20h ago
Mechanism of Action
12.1 Mechanism of Action Clotrimazole is an azole antifungal agent [see ] . 12.2 Pharmacodynamics Clotrimazole exposure-response relationships and the time course of pharmacodynamic response are unknown. 12.3 Pharmacokinetics Systemic absorption following topical administration of CLOTIC is…
Pharmacologic Class:
Azole Antifungal
Indications (5)
Worked on CLOTIC at Inpharmus? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.